A citation-based method for searching scientific literature

Joshua D Grill, David K Johnson, Jeffrey M Burns. Neurodegener Dis Manag 2013
Times Cited: 24







List of co-cited articles
163 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.
Keith A Johnson, Satoshi Minoshima, Nicolaas I Bohnen, Kevin J Donohoe, Norman L Foster, Peter Herscovitch, Jason H Karlawish, Christopher C Rowe, Maria C Carrillo, Dean M Hartley,[...]. Alzheimers Dement 2013
292
58

Disclosure of APOE genotype for risk of Alzheimer's disease.
Robert C Green, J Scott Roberts, L Adrienne Cupples, Norman R Relkin, Peter J Whitehouse, Tamsen Brown, Susan LaRusse Eckert, Melissa Butson, A Dessa Sadovnick, Kimberly A Quaid,[...]. N Engl J Med 2009
320
54

Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues.
J Scott Roberts, Laura B Dunn, Gil D Rabinovici. Neurodegener Dis Manag 2013
32
54

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Reisa A Sperling, Paul S Aisen, Laurel A Beckett, David A Bennett, Suzanne Craft, Anne M Fagan, Takeshi Iwatsubo, Clifford R Jack, Jeffrey Kaye, Thomas J Montine,[...]. Alzheimers Dement 2011
50

Disclosure of amyloid imaging results to research participants: has the time come?
Jennifer H Lingler, William E Klunk. Alzheimers Dement 2013
29
45

Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants.
Kristin Harkins, Pamela Sankar, Reisa Sperling, Joshua D Grill, Robert C Green, Keith A Johnson, Megan Healy, Jason Karlawish. Alzheimers Res Ther 2015
52
45

The A4 study: stopping AD before symptoms begin?
Reisa A Sperling, Dorene M Rentz, Keith A Johnson, Jason Karlawish, Michael Donohue, David P Salmon, Paul Aisen. Sci Transl Med 2014
441
41

Safety of disclosing amyloid status in cognitively normal older adults.
Jeffrey M Burns, David K Johnson, Edward P Liebmann, Rebecca J Bothwell, Jill K Morris, Eric D Vidoni. Alzheimers Dement 2017
38
37

Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability.
Yen Ying Lim, Paul Maruff, Christine Getter, Peter J Snyder. Alzheimers Dement 2016
37
33

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
Clifford R Jack, David A Bennett, Kaj Blennow, Maria C Carrillo, Billy Dunn, Samantha Budd Haeberlein, David M Holtzman, William Jagust, Frank Jessen, Jason Karlawish,[...]. Alzheimers Dement 2018
33

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
William E Klunk, Henry Engler, Agneta Nordberg, Yanming Wang, Gunnar Blomqvist, Daniel P Holt, Mats Bergström, Irina Savitcheva, Guo-feng Huang, Sergio Estrada,[...]. Ann Neurol 2004
29


Public perceptions of presymptomatic testing for Alzheimer disease.
Richard J Caselli, Jessica Langbaum, Gary E Marchant, Rachel A Lindor, Katherine S Hunt, Bruce R Henslin, Amylou C Dueck, Jason S Robert. Mayo Clin Proc 2014
33
29

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Marilyn S Albert, Steven T DeKosky, Dennis Dickson, Bruno Dubois, Howard H Feldman, Nick C Fox, Anthony Gamst, David M Holtzman, William J Jagust, Ronald C Petersen,[...]. Alzheimers Dement 2011
29

Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults.
Tara T Lineweaver, Mark W Bondi, Douglas Galasko, David P Salmon. Am J Psychiatry 2014
62
25

Using AD biomarker research results for clinical care: a survey of ADNI investigators.
Melanie B Shulman, Kristin Harkins, Robert C Green, Jason Karlawish. Neurology 2013
28
25

Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study.
J Scott Roberts, L Adrienne Cupples, Norman R Relkin, Peter J Whitehouse, Robert C Green. J Geriatr Psychiatry Neurol 2005
94
25

Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review.
S A S A Bemelmans, K Tromp, E M Bunnik, R J Milne, S Badger, C Brayne, M H Schermer, E Richard. Alzheimers Res Ther 2016
34
25

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.
Bruno Dubois, Howard H Feldman, Claudia Jacova, Harald Hampel, José Luis Molinuevo, Kaj Blennow, Steven T DeKosky, Serge Gauthier, Dennis Selkoe, Randall Bateman,[...]. Lancet Neurol 2014
25

Patient and caregiver reactions to clinical amyloid imaging.
Joshua D Grill, Chelsea G Cox, Sarah Kremen, Mario F Mendez, Edmond Teng, Jill Shapira, John M Ringman, Liana G Apostolova. Alzheimers Dement 2017
19
31

Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults.
Jessica Mozersky, Pamela Sankar, Kristin Harkins, Sara Hachey, Jason Karlawish. JAMA Neurol 2018
32
25

Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease.
Gaël Chételat, Renaud La Joie, Nicolas Villain, Audrey Perrotin, Vincent de La Sayette, Francis Eustache, Rik Vandenberghe. Neuroimage Clin 2013
208
20

Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study.
Serena Chao, J Scott Roberts, Theresa M Marteau, Rebecca Silliman, L Adrienne Cupples, Robert C Green. Alzheimer Dis Assoc Disord 2008
164
20


Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment.
Jennifer H Lingler, Meryl A Butters, Amanda L Gentry, Lu Hu, Amanda E Hunsaker, William E Klunk, Meghan K Mattos, Lisa S Parker, J Scott Roberts, Richard Schulz. J Alzheimers Dis 2016
22
22

A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure.
B R Ott, M A Pelosi, G Tremont, P J Snyder. Alzheimers Dement (N Y) 2016
16
31

Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results.
Jonathan Gooblar, Catherine M Roe, Natalie J Selsor, Matthew J Gabel, John C Morris. JAMA Neurol 2015
23
21


Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
Bruno Dubois, Harald Hampel, Howard H Feldman, Philip Scheltens, Paul Aisen, Sandrine Andrieu, Hovagim Bakardjian, Habib Benali, Lars Bertram, Kaj Blennow,[...]. Alzheimers Dement 2016
745
20

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Guy M McKhann, David S Knopman, Howard Chertkow, Bradley T Hyman, Clifford R Jack, Claudia H Kawas, William E Klunk, Walter J Koroshetz, Jennifer J Manly, Richard Mayeux,[...]. Alzheimers Dement 2011
20

Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context.
Gwendolien Vanderschaeghe, Jolien Schaeverbeke, Rose Bruffaerts, Rik Vandenberghe, Kris Dierickx. Alzheimers Res Ther 2017
15
33


Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.
Clifford R Jack, David S Knopman, William J Jagust, Leslie M Shaw, Paul S Aisen, Michael W Weiner, Ronald C Petersen, John Q Trojanowski. Lancet Neurol 2010
16

Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
Randall J Bateman, Chengjie Xiong, Tammie L S Benzinger, Anne M Fagan, Alison Goate, Nick C Fox, Daniel S Marcus, Nigel J Cairns, Xianyun Xie, Tyler M Blazey,[...]. N Engl J Med 2012
16


Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
Victor L Villemagne, Samantha Burnham, Pierrick Bourgeat, Belinda Brown, Kathryn A Ellis, Olivier Salvado, Cassandra Szoeke, S Lance Macaulay, Ralph Martins, Paul Maruff,[...]. Lancet Neurol 2013
16

Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials.
Joshua D Grill, Yan Zhou, David Elashoff, Jason Karlawish. Neurobiol Aging 2016
22
18

Diagnostic impact of [18F]flutemetamol PET in early-onset dementia.
Marissa D Zwan, Femke H Bouwman, Elles Konijnenberg, Wiesje M van der Flier, Adriaan A Lammertsma, Frans R J Verhey, Pauline Aalten, Bart N M van Berckel, Philip Scheltens. Alzheimers Res Ther 2017
68
16

Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations.
Michael M Witte, Norman L Foster, Adam S Fleisher, Monique M Williams, Kimberly Quaid, Michael Wasserman, Gail Hunt, J Scott Roberts, Gil D Rabinovici, James L Levenson,[...]. Alzheimers Dement (Amst) 2015
25
16

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.
Willemijn J Jansen, Rik Ossenkoppele, Dirk L Knol, Betty M Tijms, Philip Scheltens, Frans R J Verhey, Pieter Jelle Visser, Pauline Aalten, Dag Aarsland, Daniel Alcolea,[...]. JAMA 2015
792
16

Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.
Arno de Wilde, Marieke M van Buchem, René H J Otten, Femke Bouwman, Andrew Stephens, Frederik Barkhof, Philip Scheltens, Wiesje M van der Flier. Alzheimers Res Ther 2018
22
18


Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.
Christopher C Rowe, Uwe Ackerman, William Browne, Rachel Mulligan, Kerryn L Pike, Graeme O'Keefe, Henry Tochon-Danguy, Gordon Chan, Salvatore U Berlangieri, Gareth Jones,[...]. Lancet Neurol 2008
499
12

Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease.
Elizabeth M Wikler, Robert J Blendon, John M Benson. Alzheimers Res Ther 2013
28
12

Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease.
J Scott Roberts, Susan A LaRusse, Heather Katzen, Peter J Whitehouse, Melissa Barber, Stephen G Post, Norman Relkin, Kimberly Quaid, Robert H Pietrzak, L Adrienne Cupples,[...]. Alzheimer Dis Assoc Disord 2003
64
12

Frequent amyloid deposition without significant cognitive impairment among the elderly.
Howard Jay Aizenstein, Robert D Nebes, Judith A Saxton, Julie C Price, Chester A Mathis, Nicholas D Tsopelas, Scott K Ziolko, Jeffrey A James, Beth E Snitz, Patricia R Houck,[...]. Arch Neurol 2008
721
12

Public attitudes about genetic testing for Alzheimer's disease.
P J Neumann, J K Hammitt, C Mueller, H M Fillit, J Hill, N A Tetteh, K S Kosik. Health Aff (Millwood) 2001
70
12

Patient and carer views on participating in clinical trials for prodromal Alzheimer's disease and mild cognitive impairment.
Vanessa Lawrence, James Pickett, Clive Ballard, Joanna Murray. Int J Geriatr Psychiatry 2014
22
13

The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: the REVEAL Study.
Sato Ashida, Laura M Koehly, J Scott Roberts, Clara A Chen, Susan Hiraki, Robert C Green. Eur J Hum Genet 2010
35
12

Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk.
Holly C Gooding, Erin L Linnenbringer, Jeffrey Burack, J Scott Roberts, Robert C Green, Barbara B Biesecker. Patient Educ Couns 2006
44
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.